MedPath

Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?

Not Applicable
Withdrawn
Conditions
Quality of Life
Pelvic Organ Prolapse
Prolapses, Vaginal Vault
Interventions
Drug: Normal saline
Drug: Dexamethasone
Registration Number
NCT03094442
Lead Sponsor
The Cleveland Clinic
Brief Summary

The primary aim is to evaluate whether standard administration of Dexamethasone at the time of general anesthesia induction at the time of minimally invasive sacrocolpopexy (MISC) would result in improved quality of recovery (QoR).

Detailed Description

There has been a public outcry regarding the continuing rise of health care expenditures. In 1997, the estimated costs of surgery for pelvic organ prolapse (POP) were $ 100.1 million. It is important to identify interventions that would improve the QoR in this patient population and to speed-up postoperative recovery. As most of these surgeries are performed in an outpatient manner as a 23 hour observation, improved recovery may also speed discharge and free-up valuable hospital resources.

Patients will receive either Dexamethasone or placebo ( normal saline) at the time of induction of general anesthesia. QoR questionnaires, Pain scale and postoperative nausea and vomiting scale (PONV).

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  1. Women over the age of 18
  2. Women scheduled for minimally invasive sacrocolpopexy with or without concomitant anti-incontinence procedure and with or without concomitant hysterectomy
  3. American Society of Anesthesiologists (ASA) class 1-2
Read More
Exclusion Criteria
  1. Daily use of steroids, antiemetics in the month prior to surgery
  2. Chronic pain requiring daily opioid treatment
  3. History of allergy/intolerance to Dexamethasone
  4. ASA class 3
  5. Numerical Pain score (NPS) of more than 4 at baseline
  6. Renal/Liver disease
  7. Diabetes mellitus
  8. Pregnancy
  9. Inability to answer questionnaires
  10. Any systemic infections
  11. Immuno compromised status
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SalineNormal salineNormal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
DexamethasoneDexamethasoneDexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe. We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug.
Primary Outcome Measures
NameTimeMethod
Quality of recovery 40 (QoR-40)baseline, 24 hours, 6 weeks

Quality of Recovery 40 will be recorded at baseline, 24 hours and 6 weeks. The change in the mean scores will be computed for each group. The primary endpoint of change in QoR from baseline will be analyzed through t- test.

Secondary Outcome Measures
NameTimeMethod
Numerical Pain Scalebaseline, 24 hours, 6 weeks

Pain at baseline, 24 hours and 6 weeks will be recorded.

Postoperative Nausea Vomiting Scale6 weeks

Immediate nausea and vomiting 24 hours after surgery. Use of rescue antiemetics will be recorded

Trial Locations

Locations (1)

Cleveland Clinic Florida

🇺🇸

Weston, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath